Ventures · Xperienc Global Labs

Xperienc Global Labs: what it is and why it matters

Xperienc Global Labs, founded by Bairo Gonzalez in London, brings together labs, teleconsultation and translation to take clinical second opinions further.

Xperienc Global Labs is a biotechnology research and development company registered in London and founded by Bairo Leandro Gonzalez Martinez. It is developing a global health platform that brings together laboratories, teleconsultation with a clinical assistant validated by a professional, and the Global Language translator, used for clinical second opinions, not for medical reports.

The pain behind it

Before he was a founder, Bairo was a young Colombian trying to explain important things in a language that was not yet his. Anyone who has been through it knows how it goes: you understand half, you nod so as not to look lost, and you leave unsure of what you heard. At a shop counter, that is awkward. In a doctor's office, it can be dangerous.

Along the road, he saw another distance, even greater than that of language. The specialist who understands a rare case is almost always far away: in another country, behind another waiting list, with another schedule. The family that needs them doesn't even know where to start looking.

Bairo says that, on the road to rebuilding that he lived after his last fall, he trusted the plans of what he calls his guide and received, in his words, the message of Xperienc. The idea was simple to say and hard to build: clinical knowledge should not stop at a border, or at a language.

How it works, in plain words

Xperienc brings together in one place pieces that are scattered today.

Global Language. An instant translator in which patient and specialist talk, each in their own language. A mother speaks in Spanish, the specialist answers in English, and the two understand each other.
Clinical second opinion. A registered specialist from another country reads the case and writes their opinion for the doctor who already follows the patient. It is a new point of view for another professional, not a medical report. The one who decides the next step is still the person's trusted doctor.
Clinical assistant. Before the conversation, an artificial intelligence assistant organizes history, test results and questions. It prepares; the one who assesses is always a health professional. The teleconsultation was also designed for self-service booths.
Laboratory network. A platform that links those who need an analysis to laboratories with capacity, in the model Bairo describes as "Uber-like": the request finds whoever can fulfill it.
Records under the person's control. Records stay private in each user's dashboard, with integrity verifiable on BTZ Chain and the protection of qrqbits. The person decides whom to share them with.

At the center of the research is medical cannabis, treated as science: with evidence graded condition by condition and with no promise of results.

Who it is for

Patients and families facing serious decisions, who want a second look before moving forward.
Doctors who would like to hear a colleague from another country on a difficult case.
Specialists who want to see patients beyond their own borders, without having to speak each patient's language.
Laboratories with idle capacity and clinics, hospitals and governments that want to bring teleconsultation to places with no specialist.

The market

The shortage of people to provide care is global. The World Health Organization projects a shortfall of 11.1 million health workers in 2030, concentrated in low- and middle-income countries (WHO).

The technology to shorten that distance has already entered Brazilian health facilities, but slowly. According to the ICT in Health 2025 survey by Cetic.br, teleconsultation is available in 28% of health facilities, and only 18% use some form of artificial intelligence, with cost among the main barriers (Cetic.br).

And medical cannabis is no longer a niche subject. In 2025, 873,000 Brazilians used cannabis-based products, 30% more than the year before, in a market of R$970.9 million, according to the Kaya Mind yearbook (Kaya Mind). In 2026, Anvisa published a new framework for these products, which revoked RDC 327/2019 (Anvisa). More patients and clearer rules call for exactly what is missing: organized science and accessible specialists.

Where it stands today

What is on the public record: Xperienc Global Labs Ltd was incorporated in February 2026 at Companies House, in the United Kingdom, under number 17030182, with experimental research and development in biotechnology as its registered activity. Bairo is listed as director and as a person with significant control. The website xperienc.me is live.

The platform, with teleconsultation, Global Language, the laboratory network, booths and records, is in development. Xperienc has a partnership with Hospital Granja Julieta, in São Paulo, which is a separate company with its own shareholders. Bairo speaks of the ambition of placing Xperienc among the great medical cannabis laboratories of the world. It is an ambition, told as such.

Why it scales and why it matters

Xperienc grows as a network, not as a building. Every specialist who joins can serve any language Global Language covers. Every connected laboratory expands supply without a new wall. The cost of reaching a new country is, above all, software and compliance with local health rules.

And it has something software alone does not: ground. The partner hospital and the laboratories give the platform a physical place where science happens. In the ecosystem's thesis, it is this physical layer that makes the design hard to copy.

Why does it matter? Because language still decides who gets good care. In a study across six U.S. hospitals, 49.1% of adverse events among patients with limited English caused physical harm, compared with 29.5% among English speakers (Divi and colleagues, 2007). A conversation understood by both sides is part of care.

He sees Xperienc as the neural connection layer of the body he built: the system that carries information from where it is abundant to where it is lacking. It is a vision, and every step of it will depend on professionals, evidence and regulation.

Bairo's role

Bairo is the founder, director and person with significant control of Xperienc Global Labs. He designed the idea of Global Language out of his own experience as an immigrant and set from the start the rule that runs through the company: a second opinion, not a medical report; a clinical assistant, always with a professional validating.

His role is not clinical. It is that of the person who brings the pieces together, opens doors between countries and makes sure technology serves those who provide care, and not the other way around.